FACT-Colorectal: Functional Assessment of Cancer Therapy—Colorectal
Also known as: FACT-C
The FACT-Colorectal (FACT-C) is a disease-specific quality-of-life instrument designed for patients with colorectal cancer. It combines the 27-item FACT-G core (general cancer) with a 9-item colorectal-specific subscale addressing bowel function, sexual function, and cancer-related digestive concerns. Validated by Ward et al. in 1999, it is a standard endpoint in colorectal cancer clinical trials and clinical practice monitoring.
Key highlights
- Colorectal-specific subscale directly measures bowel function, continence, and sexual concerns—critical QoL domains unique to colorectal cancer and its treatments.
- Validated in large, diverse colorectal cancer populations (stages I–IV, various surgeries and chemotherapy regimens); robust psychometric properties.
- Public domain, no licensing cost; freely available in multiple languages and modalities.
- Extensive use in major cooperative group trials (SWOG, ECOG, EORTC, NCCTG); high regulatory credibility for FDA submissions and pragmatic trials.
- Captures both common cancer burden (via FACT-G) and disease-specific concerns (via CCS); enables comparative analysis of generic vs. specific impact.
Intuition
This section is available to Pro members. Upgrade to Pro
How it works
This section is available to Pro members. Upgrade to Pro
When to use it
FACT-Colorectal is indicated for patients with colorectal cancer (colon, rectal, appendiceal) at any stage, undergoing surgery, chemotherapy, radiation, or surveillance. Primary use is clinical trials assessing treatment efficacy and patient-reported outcomes; secondary use in oncology clinic monitoring (baseline, q3–6 months during active treatment, post-treatment follow-up). NOT designed for screening or diagnosis. Especially valuable when treatment decisions involve bowel/sexual function trade-offs (e.g., low anterior resection vs. abdominoperineal resection; adjuvant chemo toxicity vs. recurrence prevention).
Strengths & limitations
- Colorectal-specific subscale directly measures bowel function, continence, and sexual concerns—critical QoL domains unique to colorectal cancer and its treatments.
- Validated in large, diverse colorectal cancer populations (stages I–IV, various surgeries and chemotherapy regimens); robust psychometric properties.
- Public domain, no licensing cost; freely available in multiple languages and modalities.
- Extensive use in major cooperative group trials (SWOG, ECOG, EORTC, NCCTG); high regulatory credibility for FDA submissions and pragmatic trials.
- Captures both common cancer burden (via FACT-G) and disease-specific concerns (via CCS); enables comparative analysis of generic vs. specific impact.
- CCS subscale (9 items) may lack granularity for detailed assessment of specific bowel dysfunctions (e.g., distinguishing urgency from incontinence).
- FACT-G core assumes general cancer relevance; some items may be less salient for early-stage post-surgical patients in remission.
- No direct measure of stoma-related concerns (for patients with colostomy/ileostomy); supplementary stoma-specific scales may be needed.
- Ceiling effects in early-stage, post-surgical populations; may not detect subtle QoL improvements.
Common pitfalls
This section is available to Pro members. Upgrade to Pro
Applications
This section is available to Pro members. Upgrade to Pro
Frequently asked
Is FACT-C appropriate for patients with a colostomy or ileostomy?
Yes. FACT-C is validated in colorectal cancer patients regardless of surgical approach (sphincter-preserving, low anterior resection, abdominoperineal resection with ostomy). The CCS subscale measures bowel function and adjustment; ostomy patients may have different baseline CCS scores than non-ostomy patients, but the instrument is appropriate for both. Some studies have developed ostomy-specific addenda; consult trial protocol for guidance.
How does FACT-C compare to EORTC QLQ-CR29?
FACT-C (36 items: 27 FACT-G + 9 CCS) has a broader general cancer core plus moderate colorectal-specific detail. EORTC QLQ-CR29 (29 colorectal-specific items added to QLQ-C30 core) emphasizes detailed symptom and functional scales (micturition, defecation, bowel/abdominal symptoms). FACT-C is more prevalent in North America; EORTC more common in Europe. Both are valid; EORTC may better distinguish specific bowel dysfunctions.
What is the MCID for FACT-C, and how is it used clinically?
MCID for FACT-C total is approximately 8–10 points; for CCS subscale, approximately 3–4 points. These thresholds represent the smallest difference a patient would notice as clinically meaningful. In trials, MCID is used to help interpret statistical significance and determine clinical meaningfulness of treatment effects. In clinic, serial FACT-C changes tracked longitudinally are more informative than absolute scores for assessing treatment response and QoL trajectory.
Can FACT-C be used in recurrent or metastatic colorectal cancer?
Yes. FACT-C is validated across all colorectal cancer stages (I–IV). Metastatic patients may have lower baseline and follow-up scores reflecting higher disease and treatment burden. Interpretation should account for disease stage and prognosis; QoL expectations and MCID application differ between curative-intent and palliative-intent settings. Consider combining FACT-C with palliative-specific instruments (e.g., EORTC QLQ-C15-PAL) in advanced disease.
How are missing data handled in FACT-C scoring?
If ≥50% of subscale items are missing, do not score that subscale. If <50% are missing, impute the completed items' mean and multiply by the full subscale item count. For example, if 6 of 7 PWB items are answered, average the 6 and multiply by 7. Always report the number of missing items when presenting FACT-C results; avoid interpretation if data quality is poor (e.g., >2 missing on any subscale).
Is FACT-C a free, public-domain instrument?
Yes. FACT-C is freely available (public domain) with no licensing fees. Copies are available via FACIT.org (www.facit.org) and directly from the developers. Validated translations in 30+ languages are also free or low-cost. Use official versions to ensure psychometric integrity; ad hoc translations or modified versions may not be valid.
Sources
- 1.Ward, W. L., Hahn, E. A., Mo, F., Hernandez, L., Tulsky, D. S., & Cella, D. (1999). Reliability and validity of the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) quality of life instrument. Qual Life Res, 8(3), 181–195.
- 2.Cella, D. F., Tulsky, D. S., Gray, G., Sarafian, B., Linn, E., Bonomi, A., et al. (1993). The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol, 11(3), 570–579.
You have read it. What now?
Cite this page
ScholarGate. (2026, June 3). FACT-Colorectal. ScholarGate. https://scholargate.app/oncology/fact-colorectal